Precision medicines addressing unique diseases are poised to become more accessible

unnamed file
Credit: University of Chicago Press

Today, companies are developing new models to lower the costs of manufacturing and bring [precision medicine] drugs to more patients. Among them are companies developing new business models and services, innovative equipment for on-site manufacturing in hospitals, and improved formulation technology.

Orgenesis is among the companies turning to localization to deliver precision medicines to patients… The company’s Cell & Gene Therapy Biotech Platform incorporates the following elements: POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs); POCare Technologies, a suite of proprietary and in-licensed technologies; and POCare Network, a collaborative, international ecosystem of research institutes and hospitals. This platform, the company asserts, is about decentralization, enabling precision medicines to be prepared on-site at hospitals.

Related article:  Metabolism, environment, lifestyle are better than genetics at predicting disease risk, study says

The platform automates the production of precision medicines by validating “closed box” processes to reduce cleanroom footprints once the product gets to market. [CEO Vered] Caplan works to develop and commercialize drugs that can be licensed for use by hospitals in the Orgenesis network.

“What we do is offer a low-cost supply platform with processing and regulatory solutions that are validated in a harmonized fashion,” she details. “Essentially, we take responsibility for R&D. Our hospitals are partners, and because we’re working in a network, the economic burden isn’t high, and we can supply the therapy at a reasonable cost.”

Read the original post

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: The evolutionary history of the COVID-19 coronavirus

Infographic: The evolutionary history of the COVID-19 coronavirus

Reuters analysed over 185,000 genome samples from the Global Initiative on Sharing All influenza Data (GISAID), the largest database of ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend